

Intestinal Transport of β -Thioglycosides by Na^+ /Glucose Cotransporter

TAKASHI MIZUMA, KATSURA HAGI AND SHOJI AWAZU

Department of Biopharmaceutics and Drug Rational Research Center, School of Pharmacy, Tokyo University of Pharmacy and Life Science (TUPLS), 1432-1 Horinouchi, Hachioji, Tokyo 192-03, Japan

Abstract

Intestinal metabolism and transport of *p*-nitrophenyl β -D-thioglucoside (*p*-NP β Sglc) and *p*-nitrophenyl β -D-thiogalactoside (*p*-NP β Sgal) by the Na^+ /glucose cotransporter were studied in excised small intestine of the rat.

p-NP β Sglc and *p*-NP β Sgal were stable enough on the mucosal side to be transported to the serosal side. Transport of *p*-NP β Sglc was inhibited in the presence of phloridzin (a Na^+ /glucose cotransporter inhibitor), glucose, or 3-*O*-methylglucose (3-OMG). *p*-NP β Sglc transport was dependent on Na^+ concentration in a sigmoidal manner. The activation energy for transport was 19.4 kcal mol⁻¹. The distribution of transport activity of *p*-NP β Sglc in each region of the small intestine correlated well with that of 3-OMG. These results indicate that *p*-NP β Sglc is transported by the Na^+ /glucose cotransporter in small intestine. The order of turnover rate for glycoside transport by Na^+ /glucose cotransporter was 3-OMG > *p*-nitrophenyl β -*O*-glucoside > *p*-NP β Sglc > *p*-NP β Sgal, indicating that the presence of a galactose moiety and a sulphur between the monosaccharide moiety and aglycone decreases the turnover rate of the Na^+ /glucose cotransporter in the transport of glycosides. In an inhibition study using stable *p*-NP β Sglc as a Na^+ /glucose cotransporter-transportable marker glucoside, it was also shown that the Na^+ /glucose cotransporter recognized several types of glycosides.

In conclusion, displacement of the oxygen at carbon C-1 of glucose by sulphur in thioglycosides decreases the turnover rate of the Na^+ /glucose cotransporter, but thioglycosides are stable in the small intestine and are transported by the Na^+ /glucose cotransporter.

The intestinal Na^+ /glucose cotransporter has been shown to transport glucose and galactose conjugates (Mizuma et al 1992, 1993, 1994). This suggests the applicability of monosaccharide conjugation strategy to intestinal drug delivery by way of the Na^+ /glucose cotransporter. The order of preference of the Na^+ /glucose cotransporter for the transport of monosaccharide conjugates is: glucose conjugate > galactose conjugate and β -anomer > α -anomer. However, this information is exclusively limited to *O*-glycosides. To apply the strategy of sugar conjugation to peptides which consist of amino acids that contain sulphur, the intestinal absorption of thioglycosides possessing a thioether bond must be studied. In this paper, therefore,

intestinal transport and metabolism of thioglycosides were examined to clarify the requirement of a glycoside bond for Na^+ /glucose cotransporter-mediated transport, especially the oxygen of the ether bond between C-1 of the glucose moiety and aglycone. Recognition by the Na^+ /glucose cotransporter of several types of glycoside (Figure 1) was evaluated by studying the inhibitory effect of glycosides on Na^+ /glucose cotransporter-mediated transport of thioglycosides. The influence of the aglycone moiety on Na^+ /glucose cotransporter-mediated transport is discussed in relation to intestinal drug delivery.

Materials and Methods

Chemicals

p-Nitrophenyl β -D-thioglucoside (*p*-NP β Sglc), *p*-nitrophenyl β -D-thiogalactoside (*p*-NP β Sgal), *p*-

Correspondence: T. Mizuma, Department of Biopharmaceutics and Drug Rational Research Center, School of Pharmacy, Tokyo University of Pharmacy and Life Science (TUPLS), 1432-1 Horinouchi, Hachioji, Tokyo 192-03, Japan.
E-Mail: mizuma@ps.toyaku.ac.jp




Figure 1. Structure of *p*-nitrophenyl β -D-thioglucoside (*p*-NP β Sglc), *p*-nitrophenyl β -D-thiogalactoside (*p*-NP β Sgal) and β -O-glucosides.

nitrophenyl β -D-glucoside (*p*-NP β Oglc), *p*-aminophenyl β -D-glucoside (*p*-AP β Oglc), indoxyl β -D-glucoside (IND β Oglc), 4-methylumbelliferyl β -D-glucoside (4-MU β Oglc), D-glucopyranosyl β -D-thioglucopyranoside (thiodiglucoside), 3-O-methylglucose (3-OMG) and *p*-nitrobenzylalcohol were purchased from Sigma Co. (St Louis, MO). *p*-Nitrobenzylalcohol (*p*-NBA) and glucose assay kit (Glucose test-Wako) were purchased from Wako Pure Chemicals (Tokyo, Japan).

Intestinal transport

Intestinal transport was examined in-vitro by previously reported methods (Mizuma et al 1992). Male Wistar rats, 200–250 g (Japan Slc Inc., Shizuoka, Japan), fasted overnight, were anaesthetized with ether and intestinal blood was removed by saline perfusion. The upper, middle or lower part of the small intestine was obtained and everted. The upper part of small intestine (10 cm) was defined as the region that was 2–12 cm below the Treitz ligament. The middle part of the small intestine (10 cm) was defined as the region between points 5 cm above and 5 cm below the half-way point between the Treitz ligament and the ileocaecal junction. The lower part of small intestine (10 cm)

was defined as the region that was 2–12 cm above the ileocaecal junction.

Everted small intestine was connected to a disposable 10-mL plastic syringe, and was placed in 30 mL of incubation medium (mM: 113.3 NaCl, 4.83 KCl, 1.214 KH₂PO₄, 1.205 MgSO₄, 16.96 NaHCO₃, 10.18 Na₂HPO₄, 0.645 CaCl₂, pH 7.4) containing *p*-NP β Sglc, *p*-NP β Sgal or 3-OMG with *p*-NBA (for correction of practical absorption area) in a beaker through which gas (95% O₂, 5% CO₂) was bubbled at 37°C in a manner reported previously (Mizuma et al 1992). The serosal side was filled with 5 mL of the incubation medium without *p*-NP β Sglc, *p*-NP β Sgal or 3-OMG. When necessary, part (or all) of the sodium chloride was displaced with choline chloride. Incubation media (100 μ L) were sampled from both the serosal and the mucosal sides every 10 min for 60 min. The samples were mixed with 100 μ L of 10% perchloric acid containing 0.5 mM *p*-aminosalicylic acid as an internal standard for high-performance liquid chromatography (HPLC). After centrifugation of the mixture, for 10 min at 1200 rev min⁻¹ in a benchtop centrifuge (KM-15200, Kubota, Japan), 25 μ L of the resultant supernatant was used for HPLC.

Metabolic degradation in intestinal homogenates
Measurement of metabolic degradation of *p*-NPβSglc and *p*-NPβSgal in intestinal homogenates followed a method reported previously (Mizuma et al 1996, 1997). Ten centimeters of intestine were obtained according to the same methods used for the absorption experiments. The intestine was blotted with filter paper and the wet weight of intestine was measured. The intestine was homogenized with incubation medium using a Physcotron homogenizer (Nichion-Irika, Japan). *p*-NPβSglc or *p*-NPβSgal was incubated in 2.5% homogenate of intestine at 37°C for 60 min.

Assay of glycosides and 3-OMG

Compounds were determined by HPLC. The HPLC system consisted of a pump (880-PU, Jasco Ltd, Tokyo, Japan), UV detector (320 nm, 875-UV, Jasco Ltd), integrator (D-2500, Hitachi, Tokyo, Japan), sample injector (AS-8010, Tosoh, Tokyo, Japan) and an ODS column (TSKgel ODS-80Ts, 6 mm i.d., 150 mm length, Tosoh). The mobile phase consisting of 40% methanol and 0.05% phosphoric acid in water was used at a flow rate of 1.5 mL min⁻¹. An assay kit utilizing the *o*-toluidine method was used to determine 3-OMG (Glucose test-Wako).

Data analysis

Kinetic parameters for the transport of glycosides were obtained by fitting data to equations 1 and 2 by the nonlinear least-square fitting program, MULTI (Yamaoka et al 1981). The dependency of transport on thioglycosides concentration was analysed by equation 1.

$$v = [(V_{\max} \times C)/(K_m + C)] + (CL_{\text{pas}} \times C) \quad (1)$$

where *v* represents the transport rate, CL_{pas} represents the transport clearance by passive diffusion, and *V*_{max} and *K*_m are the maximum rate and the Michaelis constant for Na⁺/glucose cotransporter-mediated transport, respectively.

Na⁺-concentration dependency of Na⁺/glucose cotransporter-mediated transport was analysed by the Hill equation as follows (Kaunitz et al 1982):

$$v_{\text{Na}} = (V_{\max} \times C_{\text{Na}}^n)/(K_{m_{\text{Na}}}^n + C_{\text{Na}}^n) \quad (2)$$

where *C*_{Na}, *K*_{m_{Na}} and *n* are the concentration of Na⁺, the Michaelis constant and the Hill coefficient, respectively. *v*_{Na} is Na⁺-dependent transport rate, which is calculated by subtracting the transport rate in the absence of Na⁺ from that in the presence of Na⁺. *V*_{max} is the maximum rate. The

ratio (*R*_k) of turnover rate of the Na⁺/glucose cotransporter for glycoside transport to that of 3-OMG was calculated by equation 3.

$$R_k = k_{\text{gly}}/k_{\text{3-OMG}} = V_{\max, \text{gly}}/V_{\max, \text{3-OMG}} \quad (3)$$

where *k*_{gly} and *k*_{3-OMG} are the turnover rate for transport of glycosides and 3-OMG, respectively. *V*_{max, gly} and *V*_{max, 3-OMG} are the maximum rate (*V*_{max}) of the transport of glycosides and 3-OMG, respectively. *V*_{max} (mole unit per time per a unit of length of small intestine) is expressed by equation 4.

$$V_{\max} = (n \times k)/\text{Avogadro's number} \quad (4)$$

where *n* and *k* represent the number of cotransporters per unit of length of small intestine and the turnover rate of the cotransporter for a round trip between the outside and inside of the cell, respectively. Statistical analysis of the data was performed by Tukey–Kramer or Dunnett's multiple comparisons post test following analysis of variance.

Results

Effects of phloridzin and absence of Na⁺ on serosal appearance of *p*-NPβSglc

Figure 2 shows the concentration–time profiles of *p*-NPβSglc on the serosal side. *p*-NPβSglc concentration increased with time, but the rate of serosal appearance of *p*-NPβSglc decreased in the presence of phloridzin (Na⁺/glucose cotransporter inhibitor) and in the absence of Na⁺ (cosubstrate of




Figure 2. Time-course of serosal appearance of *p*-NPβSglc (0.25 mM) following transport across rat small intestine (upper region) under various conditions. Data represent means ± s.e.m. (*n* = 4–8). Control, ○; phloridzin, ●; Na⁺-free, ●; Na⁺-free + phloridzin, □.




Figure 3. Eadie-Hofstee plots for transport of *p*-NPβSglc (A), *p*-NPβSgal (B) and 3-OMG (C) across rat small intestine (upper region). Data represent means \pm s.e.m., $n = 3-8$. Curves were obtained by fitting data to equation 1 (see text).

Na⁺/glucose cotransporter). The concentration of *p*-NPβSglc on the mucosal side under each condition did not markedly decrease after 60 min (data not shown). Other compounds were not detected on either the mucosal or the serosal side. Similar results were observed for *p*-NPβSgal absorption, although its transport rate was lower than that of *p*-NPβSglc (data not shown).

Stability of p-NPβSglc and p-NPβSgal in intestinal homogenates

The concentration of *p*-NPβSglc in the homogenate of the upper part of the small intestine was constant for 60 min, indicating that this thioglucoside was extremely stable even in intestinal homogenates (data not shown). Similar stability was observed for *p*-NPβSgal.

Concentration dependency of the transport of p-NPβSglc, p-NPβSgal and 3-OMG

Figures 3a-c show Eadie-Hofstee plots of the intestinal transport of *p*-NPβSglc, *p*-NPβSgal and 3-OMG. These figures indicate that the transport of all 3 consists of both saturable and non-saturable components. Kinetic parameters for the transport of 3-OMG and glycosides, which were obtained by equation 1, are summarized in Table 1. The K_m values indicated that the order of affinity for the Na⁺/glucose cotransporter was *p*-NPβOglc > *p*-NPβSglc > *p*-NPβSgal > 3-OMG. The order of V_{max} (turnover rate) was 3-OMG > *p*-NPβOglc > *p*-NPβSglc > *p*-NPβSgal. The order of V_{max}/K_m values, which represent specific transport activity of Na⁺/glucose cotransporter-mediated transport, was 3-OMG = *p*-NPβOglc > *p*-NPβSglc > *p*-NPβSgal.

Effect of transport inhibitors on p-NPβSglc transport

Table 2 shows the effect of Na⁺/glucose cotransporter inhibitors on *p*-NPβSglc transport. Transport decreased in the presence of Na⁺/glucose cotransporter-transportable substrate (glucose or 3-OMG) and in the presence of Na⁺/glucose cotransporter inhibitor (phloridzin). Transport was also inhibited by 2,4-dinitrophenol. These results indicate that *p*-NPβSglc is transported by the Na⁺/glucose cotransporter.

Effect of Na⁺ concentration on p-NPβSglc transport

Figure 4 shows the effect of Na⁺ concentration on *p*-NPβSglc transport. The transport was dependent

Table 1. Kinetic parameters of intestinal transport of glucose derivatives in rat intestine.

	Km (mM)	Vmax (nmol min ⁻¹ cm ⁻¹)	Vmax/Km (μL min ⁻¹ cm ⁻¹)	Rk	CLpas (μL min ⁻¹ cm ⁻¹)
3-OMG	5.57 ± 1.78	29.2 ± 6.45	5.240	1.0000	0.56 ± 0.13
<i>p</i> -NPβOglc ^a	0.59 ± 0.18	3.02 ± 0.38	5.120	0.1034	0.88 ± 0.04
<i>p</i> -NPβSglc	1.11 ± 0.65	1.46 ± 0.71	1.320	0.0500	0.45 ± 0.08
<i>p</i> -NPβSgal	1.45 ± 0.82	0.37 ± 0.49	0.255	0.0127	0.55 ± 0.07

Data represent fitted values ± s.d. (except the values of Vmax/Km). ^aValues calculated from the data of Mizuma et al (1992).

on Na⁺ concentration in a sigmoidal manner, indicating a cooperative effect of Na⁺ on the Na⁺/glucose cotransporter-mediated transport of *p*-NPβSglc. Nonlinear least-square fitting of data to equation 2 gave $n = 1.8$ and $K_m = 28.1$ mM.

Temperature dependency of *p*-NPβSglc transport

Figure 5 shows the Arrhenius plot of Na⁺/glucose cotransporter-mediated transport of *p*-NPβSglc. Transport of *p*-NPβSglc by the Na⁺/glucose cotransporter was dependent on temperature and its activation energy was 19.4 kcal mol⁻¹.

Comparison of Na⁺/glucose cotransporter-mediated transport of *p*-NPβSglc and 3-OMG in the upper, middle and lower regions of small intestine

Table 3 shows the transport clearance of *p*-NPβSglc and 3-OMG in each part of small intestine in the presence and absence of Na⁺, and Na⁺/glucose cotransporter-mediated transport clearances. The clearance for Na⁺/glucose cotransporter-mediated transport of *p*-NPβSglc in the upper part of small intestine was nearly the same as in the middle part, but was higher than in the lower part. Similar regional differences were observed for the transport of 3-OMG.

Inhibition activity of several types of glycosides on the transport of *p*-NPβSglc by the Na⁺/glucose cotransporter

Table 4 shows the inhibitory effects of *O*-glycosides and *S*-glycosides on the transport of *p*-NPβSglc. The transport of *p*-NPβSglc was significantly decreased in the presence of *O*-glycosides such as *p*-NPβOglc, *p*-APβOglc, INDβOglc and 4-MUβOglc. The transport of *p*-NPβSglc was inhibited by *p*-NPβSgal, but not by thiodigluconide.

Discussion

The transportability of *p*-NPβSglc and *p*-NPβSgal across the intestinal barrier to the serosal side was

Table 2. Effects of transport inhibitors on transport of *p*-NPβSglc (0.25 mM) across rat small intestine.

Conditions	Amount transported (nmol/30 min cm ⁻¹)
Control	9.69 ± 0.39 (8)
Glucose (25 mM)	3.58 ± 0.30* (3)
3-OMG (25 mM)	5.47 ± 1.31* (4)
Phloridzin (1 mM)	4.19 ± 0.27* (4)
2,4-Dinitrophenol (2 mM)	7.16 ± 0.36* (4)

Data represent means ± s.e.m., $n = 4-8$, indicated in parentheses. * $P < 0.05$, compared with control, obtained by Dunnett's multiple comparison post test following analysis of variance. The upper region of the small intestine was used.

evaluated. *p*-NPβSglc and *p*-NPβSgal are completely stable in the intestinal tract and intestinal homogenates (data not shown). 3-OMG was also shown to be stable on the mucosal side, although glucose was metabolized on both sides, where the




Figure 4. Na⁺-concentration dependency of *p*-NPβSglc (0.25 mM) transport by the Na⁺/glucose cotransporter of rat small intestine (upper region). The dotted curve was obtained by fitting data to equation 2 (see text). Data represent means ± s.e.m., $n = 4-6$.




Figure 5. Arrhenius plot of Na^+ /glucose cotransporter-mediated transport of $p\text{-NP}\beta\text{Sglc}$ (0.25 mM) across rat small intestine (upper region). Data represent means ($n=3-8$). Na^+ /glucose cotransporter-mediated transport was calculated by subtracting the amount of $p\text{-NP}\beta\text{Sglc}$ transported in the absence of Na^+ from the amount transported under control conditions.

elimination clearance of 1 mM glucose on the mucosal side was $42.9 \mu\text{L min}^{-1} \text{cm}^{-1}$, and the concentrations of glucose on the serosal side after 20 and 60 min were 20 and $12 \mu\text{M}$, respectively (data not shown). Therefore, the transportability of 3-OMG transport was calculated by the same method as the transport of $p\text{-NP}\beta\text{Sglc}$ and $p\text{-NP}\beta\text{Sgal}$.

The transport of $p\text{-NP}\beta\text{Sglc}$ was concentration dependent (Figure 3a) and decreased in the presence of either Na^+ /glucose cotransporter inhibitor or Na^+ /glucose cotransporter-transportable substrates (Figure 2, Table 2). The transport of $p\text{-NP}\beta\text{Sglc}$ depended on temperature, and the activation energy for Na^+ /glucose cotransporter-

Table 3. Comparison of absorption clearances in regions of rat small intestine.

Region	$p\text{-NP}\beta\text{Sglc}$ 0.25 mM	3-OMG 5 mM
Total		
Upper	$1.43 \pm 0.10^*$	$1.96 \pm 0.11^*$
Middle	$1.65 \pm 0.17^*$	$1.92 \pm 0.03^*$
Lower	0.908 ± 0.077	0.705 ± 0.058
Na^+ -dependent		
Upper	0.855 ± 0.096	$1.28 \pm 0.11^*$
Middle	1.02 ± 0.17	$1.23 \pm 0.03^*$
Lower	0.623 ± 0.077	0.397 ± 0.058
Na^+ -independent		
Upper	$0.576 \pm 0.020^*$	0.682 ± 0.089
Middle	$0.631 \pm 0.075^*$	0.689 ± 0.202
Lower	$0.285 \pm 0.026^*$	0.308 ± 0.072

Values represent means \pm s.e.m., $n=4-8$, $\mu\text{L min}^{-1} \text{cm}^{-1}$. * $P < 0.05$, NS for lower region, obtained by Tukey-Kramer multiple comparison post test following analysis of variance.

Table 4. Inhibitory effects of *O*-glycosides and *S*-glycosides (25 mM) on transport of $p\text{-NP}\beta\text{Sglc}$ (0.25 mM) across rat small intestine.

Condition	Absorption clearance of $p\text{-NP}\beta\text{Sglc}$ ($\mu\text{L min}^{-1} \text{cm}^{-1}$)
Control	1.43 ± 0.10 (8)
$p\text{-NP}\beta\text{Oglc}$	$0.549 \pm 0.023^*$ (4)
$p\text{-AP}\beta\text{Oglc}$	$0.471 \pm 0.052^*$ (3)
IND βOglc	$0.467 \pm 0.058^*$ (3)
4-MU βOglc	$0.439 \pm 0.010^*$ (3)
Thiodiglusoside	1.48 ± 0.02 (3)
$p\text{-NP}\beta\text{Sglc}$	$0.798 \pm 0.111^*$ (4)

$p\text{-NP}\beta\text{Oglc}$, *p*-nitrophenyl β -D-glucoside; $p\text{-AP}\beta\text{Oglc}$, *p*-aminophenyl β -D-glucoside; IND βOglc , indoxyl β -D-glucoside; 4-MU βOglc , 4-methylumbelliferyl β -D-glucoside; thiodiglusoside, D-glucosyl β -D-thioglusoside; $p\text{-NP}\beta\text{Sgal}$, *p*-nitrophenyl β -D-thiogalactoside. The upper region of the small intestine was used. Data represent means \pm s.e.m. ($n=4-8$, indicated in parentheses). * $P < 0.05$, vs control, obtained by Dunnett's multiple comparison post tests following analysis of variance.

mediated transport was $19.4 \text{ kcal mol}^{-1}$ (Figure 5), approximately comparable with the value reported by Loo et al (1996). These results suggest that $p\text{-NP}\beta\text{Sglc}$ is transported by the Na^+ /glucose cotransporter. The transport rate of $p\text{-NP}\beta\text{Sglc}$ versus the concentration of Na^+ was sigmoidal (Figure 4), and fitted well to equation 2 based on the Hill equation of Na^+ for the Na^+ /glucose cotransporter (Kaunitz et al 1982). The values for n of 1.8 and K_m of 28.1 mM were similar to the reported values for glucose transport ($n=1.9$ and $K_m \sim 38 \text{ mM}$; Kaunitz et al 1982). Similarly, Ikeda et al (1989) reported that $n=1.5$ and $K_m=32 \text{ mM}$ with the oocytes cloned from rabbit small intestine, and $n=1.7$ and $K_m=52 \text{ mM}$ with brush-border membrane vesicles of rabbit small intestine. Na^+ /glucose cotransporter-mediated transport of $p\text{-NP}\beta\text{Sglc}$ was also suggested by an electrophysiological experiment, in which a short-circuit current was induced by $p\text{-NP}\beta\text{Sglc}$, and was inhibited by the presence of phloridzin (Mizuma 1998). Therefore, it is likely that $p\text{-NP}\beta\text{Sglc}$ is transported by the Na^+ /glucose cotransporter.

The K_m of $p\text{-NP}\beta\text{Sglc}$ was lower than that of 3-OMG or the reported value (2.8 mM) of glucose (Thomson et al 1982), indicating that the affinity of $p\text{-NP}\beta\text{Sglc}$ for the Na^+ /glucose cotransporter was higher than that of 3-OMG. Since the K_m of $p\text{-NP}\beta\text{Oglc}$ was also lower than that of 3-OMG, we

conclude that aglycone increases the affinity for the Na⁺/glucose cotransporter. The value of V_{\max}/K_m of *p*-NPβOglc was similar to that of 3-OMG, indicating that the specific transport activity of *p*-NPβOglc was comparable with that of 3-OMG, and an order of 3-OMG \cong *p*-NPβOglc > *p*-NPβSglc > *p*-NPβSgal.

On the other hand, the R_k (or V_{\max}) of *p*-NPβSglc, *p*-NPβSgal and *p*-NPβOglc were lower than that of 3-OMG (Table 1), indicating that conjugation of an aglycone to glucose decreases the turnover rate of the Na⁺/glucose cotransporter. Furthermore, the R_k of glycosides are in the order of *p*-NPβOglc > *p*-NPβSglc and *p*-NPβSglc > *p*-NPβSgal, indicating that the presence of a galactose moiety and a sulphur between the monosaccharide moiety and aglycone decreases the turnover rate of the Na⁺/glucose cotransporter for glycoside transport. These results indicate that any modification of glycosides may affect not only affinity for the Na⁺/glucose cotransporter but also the turnover rate of the Na⁺/glucose cotransporter. In a previous study we hypothesized that the Na⁺/glucose cotransporter might have spare space localized around the β-position rather than the α-position at carbon C-1 of glucose, which is space for aglycone to transport monosaccharide conjugates (Mizuma et al 1998). An NMR study showed that the glucose conformation of *p*-NPβSglc was ⁴C₁ chair form, the same as that of *p*-NPβOglc (unpublished data). Since the aglycone of *p*-NPβSglc and *p*-NPβOglc is the same, it is suggested that sulphur changes the conformation of the glycoside to decrease the affinity and the turnover rate. *p*-NPβSglc was also transported in the middle and lower regions of the small intestine. The distribution of Na⁺/glucose cotransporter-mediated transport of *p*-NPβSglc was similar to that of 3-OMG, indicating that *p*-NPβSglc was absorbed by the Na⁺/glucose cotransporter in all regions of the small intestine (Table 3). Na⁺-dependent absorption clearances of *p*-NPβSglc were approximately 0.6–1.0 μL min⁻¹ cm⁻¹. This value corresponds to half to one-third that of orally active paracetamol (2 μL min⁻¹ cm⁻¹, unpublished results).

p-NPβSglc is UV-detectable, stable in the intestine and transportable by the Na⁺/glucose cotransporter. However, *O*-glucosides such as *p*-NPβOglc and 1-naphthyl β-*O*-glucoside that were able to be transported by the Na⁺/glucose cotransporter, were partially desglucosylated (Mizuma et al 1993, 1994). Therefore, *p*-NPβSglc was used as a Na⁺/glucose cotransporter-mediated transportable marker glucoside to study the inhibition of several types of glycoside. The transport of *p*-NPβSglc, which was inhibited by α-methyl glucose (unpub-

lished result), was inhibited equally by *O*-glucosides and phloridzin, indicating that these glycosides are recognized by the Na⁺/glucose cotransporter (Table 4). *p*-NPβSgal inhibited *p*-NPβSglc transport, but thiodiglucoside did not, indicating that aglycone affects the recognition of thioglycosides by the Na⁺/glucose cotransporter.

In summary, *p*-NPβSglc and *p*-NPβSgal were shown to be transported by the Na⁺/glucose cotransporter in small intestine. It was also shown that conjugation of an aglycone to glucose increases the affinity for the Na⁺/glucose cotransporter, but decreases the turnover rate of the Na⁺/glucose cotransporter. By using stable *p*-NPβSglc as a Na⁺/glucose cotransporter-transportable marker glucoside, it was shown that the Na⁺/glucose cotransporter recognized several types of glycoside.

Acknowledgements

The authors thank Ms Noriko Hisaki and Mr Yoshiyuki Hosoi for technical assistance.

References

- Kaunitz, J. D., Gunther, R., Wright, E. M. (1982) Involvement of multiple sodium ions in intestinal D-glucose transport. *Proc. Natl Acad. Sci. USA* 79: 2315–2318
- Ikeda, T. S., Hwang, E.-S., Coady, M. J., Hirayama, B. A., Hediger, M. A., Wright, E. M. (1989) Characterization of a Na⁺/glucose cotransporter cloned from rabbit small intestine. *J. Membrane Biol.* 110: 87–95
- Loo, D. D. F., Zeuthen, T., Chandy, G., Wright, E. M. (1996) Cotransport of water by the Na⁺/glucose cotransporter. *Proc. Natl Acad. Sci. USA* 93: 13367–13370
- Mizuma, T. (1998) Carrier-mediated oral drug delivery utilizing glucose transporter: importance of turnover rate of transporter in drug delivery. Presented at The Ninth Japanese-American Conference on Pharmacokinetics and Biopharmaceutics, Nagoya.
- Mizuma, T., Ohta, K., Hayashi, M., Awazu, S. (1992) Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improvement of poorly absorbable drugs. *Biochem. Pharmacol.* 43: 2037–2039
- Mizuma, T., Ohta, K., Hayashi, M., Awazu, S. (1993) Comparative study of active absorption by the intestine and disposition of anomers of sugar-conjugated compounds. *Biochem. Pharmacol.* 45: 1520–1523
- Mizuma, T., Ohta, K., Awazu, S. (1994) The β-anomeric and glucose preferences of glucose transport carrier for intestinal active absorption of monosaccharide conjugates. *Biochim. Biophys. Acta* 1200: 117–122
- Mizuma, T., Ohta, K., Koyanagi, A., Awazu, S. (1996) Improvement of intestinal absorption of leucine enkephalin by sugar coupling and peptidase inhibitors. *J. Pharm. Sci.* 85: 854–857

- Mizuma, T., Koyanagi, A., Awazu, S. (1997) Intestinal transport and metabolism of analgesic dipeptides, kyotorphin: rate-limiting factor in intestinal absorption of peptide as drug. *Biochim. Biophys. Acta* 1335: 111–119
- Mizuma, T., Nagamine, Y., Dobashi, A., Awazu, S. (1998) Factors that cause the β -anomeric preference of Na^+ /glucose transporter for intestinal transport of monosaccharide conjugates. *Biochim. Biophys. Acta* 1381: 340–346
- Thomson, A. B. R., Hotke, C. A., Weinstein, W. M. (1982) Comparison of kinetic constants of hexose uptake in four animal species and man. *Comp. Biochem. Physiol.* 72A: 225–236
- Yamaoka, K., Tanigawara, Y., Nakagawa, T., Uno, T. (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. *J. Pharmacobio-Dyn.* 4: 879–885